Majid Naderi
Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
[ 1 ] - Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...
[ 2 ] - Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...
[ 3 ] - گزارش کمبود فاکتور 13 انعقادی در سیستان و بلوچستان
چکید ه سابقه و هدف کمبود فاکتور13 ، یکی از نادرترین اختلالات انعقادی بوده که دارای شیوع 1 در هر 1 تا 3 میلیون نفر می‌باشد. کمبود این فاکتور موجب بروز تظاهرات بالینی مانند خونریزی مغزی، سقط جنین وخونریزی تاخیری می‌گردد. مطالعه حاضر در نظر دارد به بررسی علایم بالینی در بیماران مبتلا به کمبود شدید فاکتور13 بپردازد. مواد و روش‌ها مطالعه توصیفی حاضر طی سال 1390 بر روی 205 بیمار مبتلا به کم...